Cargando…

Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports

Detalles Bibliográficos
Autores principales:	Pini, Laura, Caruso, Cristiano, Colantuono, Stefania, Bagnasco, Diego, Maxwell, Aoife, Price, Robert G., Howarth, Peter, Canonica, Giorgio Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517195/ https://www.ncbi.nlm.nih.gov/pubmed/34691389 http://dx.doi.org/10.1002/clt2.12067

Ejemplares similares

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Varricchi, Gilda, et al.
Publicado: (2016)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
por: Harrison, Tim, et al.
Publicado: (2020)

Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
por: Caruso, C., et al.
Publicado: (2020)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
por: Varricchi, Gilda, et al.
Publicado: (2017)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
por: Pavord, Ian, et al.
Publicado: (2023)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
por: Bagnasco, Diego, et al.
Publicado: (2023)

Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies
por: Casale, Thomas B., et al.
Publicado: (2022)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Emma, Rosalia, et al.
Publicado: (2018)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
por: Pouliquen, I. J., et al.
Publicado: (2017)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
por: Gupta, Atul, et al.
Publicado: (2019)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
por: Crimi, Claudia, et al.
Publicado: (2020)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
por: Pavord, Ian D., et al.
Publicado: (2022)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET
por: Liu, Mark C., et al.
Publicado: (2022)

Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
por: Bagnasco, Diego, et al.
Publicado: (2017)

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
por: Liu, Mark C., et al.
Publicado: (2021)

REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study
por: Domingo Ribas, Christian, et al.
Publicado: (2021)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
por: Matsuno, Osamu, et al.
Publicado: (2019)

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
por: Montero-Pérez, Olalla, et al.
Publicado: (2019)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma
por: Kobayashi, Konomi, et al.
Publicado: (2021)

Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma
por: Hassani, Marwan, et al.
Publicado: (2021)

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)
por: Moore, Wendy C., et al.
Publicado: (2022)

Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study
por: Domingo Ribas , Christian, et al.
Publicado: (2021)

Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype
por: González-Pérez, Ruperto, et al.
Publicado: (2022)

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs
por: Llanos, Jean-Pierre, et al.
Publicado: (2020)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
por: Ghassemian, Arian, et al.
Publicado: (2021)

Type 2 immunity in asthma
por: Caminati, Marco, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k1909n688gtk80361aev45elo3